Liver Transplantation Clinical Trial
Official title:
Endoscopic Evaluation in Transplantation Candidates - Frequency and Prognostic Relevance of Upper and Lower Gastrointestinal Tract Findings
In consideration of the limited supply of donor organs, the careful selection of transplant
candidates is essential to optimize patient outcome after transplantation. Therefore an
extensive evaluation of transplant candidates including among others
esophagogastroduodenoscopy (EGD) and colonoscopy has been implemented in our centre. The
data regarding the prevalence of upper and lower gastrointestinal (GI) pathology in
transplant candidates are contradictory and are based on only a few retrospective studies,
which often include only a subgroup of transplant candidates. The goal of this project is a
prospective evaluation of the frequency of GI pathologies in transplant candidates with
specific focus on the following questions:
1. Are there GI-pathologies that occur at a higher prevalence in transplant candidates
than described in the general population and is there an increase of GI-pathologies
since the introduction of the urgency-based organ allocation leading to sicker
transplant candidates?
2. What is the influence of endoscopic findings on patient management before
transplantation?
3. Which risk factors can be identified that predict the presence of GI-lesions?
4. Is there a subgroup of patients, in which screening colonoscopy before liver
transplantation can not be recommended considering the cost/benefit ratio?
5. Is there a correlation of endoscopic findings with outcome after liver transplantation
or with gastrointestinal complications during or after transplantation (e.g.
gastrointestinal bleeding, perforation or gastrointestinal malignancy)?
Background:
The introduction of a MELD (model for end-stage liver disease) based necessity-oriented
allocation system for liver transplantation (OLT) has lead to an increasing number of
patients with advanced liver disease on the waiting list. Hence it is essential to optimize
outcome after transplantation in this high-risk patient collective in order to best utilize
the limited supply of donor organs. To achieve this goal, the careful selection of
appropriate transplantation candidates is based on an extensive evaluation of the patients
including cardiac, pulmonary and renal testing and different imaging methods to exclude
malignancies or an infective focus. As in many other institutions also in the Medical School
Hannover (MHH) esophagogastroduodenoscopy (EGD) and colonoscopy are standard procedures
during evaluation for liver transplantation. The rationale to perform these procedures is to
identify patients with medical conditions that might limit their outcome after OLT. Some
endoscopic findings as for example esophageal varices, gastric or duodenal ulcer or colon
adenoma can be treated before transplantation, so that the patient enters the waiting list
in a better medical condition. If gastrointestinal malignancies are detected, the patient
will no longer be considered a candidate for OLT, unless curative treated. The detection of
premalignant changes (high grade adenomas, barrett's esophagus etc.) is of great importance,
since the immunosuppressed liver transplantation recipients are probably at a higher risk to
progress to malignancy.
So far the data regarding the prevalence of upper and lower gastrointestinal pathologies in
transplantation candidates are contradictory and are based on only a few retrospective
studies. These studies often include only a subgroup of transplantation candidates. Many
centres perform screening colonoscopy during OLT evaluation only in patients greater than
age 45 or 50, although until today there is no clear evidence, that younger patients do not
have a benefit from screening colonoscopy.
So far it is not known if certain preoperative endoscopic findings correlate with
postoperative gastrointestinal complications. Such a correlation, e.g. between
diverticulosis and postoperative colon perforation or peritonitis due to diverticulitis,
could be highly relevant for patient management before and after OLT.
Methods:
After signing informed consent the results of EGD and colonoscopy of all patients evaluated
for OLT at the MHH together with laboratory and clinical data will be entered in a database.
After follow up for at least one year these data will be analyzed. Descriptive statistics as
well as a multivariate analysis will be performed, to find out the frequency of endoscopic
diagnoses in transplantation candidates and to look for correlations between these findings
and patient outcome after OLT.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 |